Cite
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
MLA
Zhu, Qiyu, et al. “The Efficacy and Safety of PARP Inhibitors in MCRPC with HRR Mutation in Second-Line Treatment: A Systematic Review and Bayesian Network Meta-Analysis.” BMC Cancer, vol. 24, no. 1, June 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-024-12388-2.
APA
Zhu, Q., Chen, J., Liu, H., Zhao, J., Xu, C., Sun, G., & Zeng, H. (2024). The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis. BMC Cancer, 24(1), 1–10. https://doi.org/10.1186/s12885-024-12388-2
Chicago
Zhu, Qiyu, Junru Chen, Haoyang Liu, Jinge Zhao, Chenhao Xu, Guangxi Sun, and Hao Zeng. 2024. “The Efficacy and Safety of PARP Inhibitors in MCRPC with HRR Mutation in Second-Line Treatment: A Systematic Review and Bayesian Network Meta-Analysis.” BMC Cancer 24 (1): 1–10. doi:10.1186/s12885-024-12388-2.